IFN-DLI for Relapsed Acute Leukemia After Allo-SCT
Primary Purpose
Leukemia
Status
Completed
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily
Sponsored by

About this trial
This is an interventional treatment trial for Leukemia
Eligibility Criteria
Inclusion Criteria:
DLI Recipient
- Relapsed AML or ALL ≥ 60 days after allogeneic SCT.
- Evidence of residual donor chimerism on most recent analysis (within 4 weeks of enrollment).
- Age ≥ 18 years of age,
- Karnofsky performance status ≥ 60%.
- Absence of active GVHD and off immunosuppression. Subjects on tapering prednisone will be eligible if their dose is 0.25 mg/kg or less and being actively tapered. We suggest a 28 day waiting period off of immunosuppression but some subjects with rapidly progressive disease may need to be treated before 30 days and will still be eligible.
- Adequate organ function: Cr ≤ 2 mg/dL; ALT/AST < 3x ULN, direct bili <3x ULN.
- Matched sibling or un-related donor (A, B, C, and DR) available to undergo leukopheresis.
- Subjects must be able to sign consent and be willing and able to comply with scheduled visits, treatment plan and laboratory testing.
- Willing to provide blood samples for research purposes.
- Willing to adhere to medically accepted form of birth control to prevent pregnancy (includes: complete abstention from intercourse, condoms, diaphragms, cervical cap, intra-uterine device, history of surgical sterility - tubal ligation or vasectomy in patient or partner, or oral contraceptive).
DLI Donor
- HLA identical to recipient subject.
- Considered medically eligible for leukopheresis procedure by independent donor physician (University of Pennsylvania physician who is not the recipient's primary transplant physician for related donors; physician designated by National Marrow Donor Program for unrelated donors).
- Considered medically eligible to receive G-CSF (filgrastim) by independent donor physician.
Exclusion Criteria
Recipient
- Prior cell therapy for relapse within the past 90 days.
- Requirement for active immunosuppression to treat GVHD.
- Pregnant or lactating women. The safety of this therapy on unborn children and effects on breast milk are not known.
- Uncontrolled active infection
- Any uncontrolled active medical disorder that would preclude participation as outlined.
Donor
- Unable to participate in a leukopheresis procedure or receive G-CSF (filgrastim).
Sites / Locations
- Abramson Cancer Center of the University of Pennsylvania
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Subject Recipients
Subject Donors
Arm Description
Outcomes
Primary Outcome Measures
Number of Adverse Events
Secondary Outcome Measures
overall survival
disease-free survival
Full Information
NCT ID
NCT02331706
First Posted
December 22, 2014
Last Updated
April 20, 2020
Sponsor
Abramson Cancer Center at Penn Medicine
1. Study Identification
Unique Protocol Identification Number
NCT02331706
Brief Title
IFN-DLI for Relapsed Acute Leukemia After Allo-SCT
Official Title
A Pilot Study to Determine the Feasibility of Conventional Induction Chemotherapy Followed by G-CSF Mobilized Donor Leukocyte Infusion (DLI) and IFN-α (IFN-DLI) for Relapsed Acute Leukemia After Allogeneic Stem Cell Transplantation.
Study Type
Interventional
2. Study Status
Record Verification Date
April 2020
Overall Recruitment Status
Completed
Study Start Date
December 2014 (Actual)
Primary Completion Date
November 11, 2016 (Actual)
Study Completion Date
November 11, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Abramson Cancer Center at Penn Medicine
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This trial is designed to determine the feasibility of conventional induction chemotherapy, IFNand G-CSF mobilized DLI (IFN-DLI) in subjects with relapsed AML and ALL after allo-SCT.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Leukemia
7. Study Design
Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
16 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Subject Recipients
Arm Type
Experimental
Arm Title
Subject Donors
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily
Primary Outcome Measure Information:
Title
Number of Adverse Events
Time Frame
2 years
Secondary Outcome Measure Information:
Title
overall survival
Time Frame
2 years
Title
disease-free survival
Time Frame
2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
DLI Recipient
Relapsed AML or ALL ≥ 60 days after allogeneic SCT.
Evidence of residual donor chimerism on most recent analysis (within 4 weeks of enrollment).
Age ≥ 18 years of age,
Karnofsky performance status ≥ 60%.
Absence of active GVHD and off immunosuppression. Subjects on tapering prednisone will be eligible if their dose is 0.25 mg/kg or less and being actively tapered. We suggest a 28 day waiting period off of immunosuppression but some subjects with rapidly progressive disease may need to be treated before 30 days and will still be eligible.
Adequate organ function: Cr ≤ 2 mg/dL; ALT/AST < 3x ULN, direct bili <3x ULN.
Matched sibling or un-related donor (A, B, C, and DR) available to undergo leukopheresis.
Subjects must be able to sign consent and be willing and able to comply with scheduled visits, treatment plan and laboratory testing.
Willing to provide blood samples for research purposes.
Willing to adhere to medically accepted form of birth control to prevent pregnancy (includes: complete abstention from intercourse, condoms, diaphragms, cervical cap, intra-uterine device, history of surgical sterility - tubal ligation or vasectomy in patient or partner, or oral contraceptive).
DLI Donor
HLA identical to recipient subject.
Considered medically eligible for leukopheresis procedure by independent donor physician (University of Pennsylvania physician who is not the recipient's primary transplant physician for related donors; physician designated by National Marrow Donor Program for unrelated donors).
Considered medically eligible to receive G-CSF (filgrastim) by independent donor physician.
Exclusion Criteria
Recipient
Prior cell therapy for relapse within the past 90 days.
Requirement for active immunosuppression to treat GVHD.
Pregnant or lactating women. The safety of this therapy on unborn children and effects on breast milk are not known.
Uncontrolled active infection
Any uncontrolled active medical disorder that would preclude participation as outlined.
Donor
- Unable to participate in a leukopheresis procedure or receive G-CSF (filgrastim).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Porter, MD
Organizational Affiliation
Abramson Cancer Center at Penn Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Abramson Cancer Center of the University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
12. IPD Sharing Statement
Learn more about this trial
IFN-DLI for Relapsed Acute Leukemia After Allo-SCT
We'll reach out to this number within 24 hrs